146. Distinct functional constraints driving conservation of the cofilin N-terminal regulatory tail.
Sexton JA, Potchernikov T, Bibeau JP, Casanova-Sepúlveda G, Cao W, Lou HJ, Boggon TJ, De La Cruz E, Turk BE.
Nature Communications. 2024; 15(1): 1426.

145. Autoregulation of the LIM kinases by their PDZ domain.
Casanova-Sepúlveda G, Sexton JA, Turk BE, Boggon TJ.
Nature Communications. 2023; 14(1): 8441.

144. Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations.
Zhao S, Mekbib KY, van der Ent MA, Allington G, Prendergast A, Chau JE, Smith H, Shohfi J, Ocken J, Duran D, Furey CG, Hao LT, Duy PQ, Reeves BC, Zhang J, Nelson-Williams C, Chen D, Li B, Nottoli T, Bai S, Rolle M, Zeng X, Dong W, Fu PY, Wang YC, Mane S, Piwowarczyk P, Fehnel KP, See AP, Iskandar BJ, Aagaard-Kienitz B, Moyer QJ, Dennis E, Kiziltug E, Kundishora AJ, DeSpenza T Jr, Greenberg ABW, Kidanemariam SM, Hale AT, Johnston JM, Jackson EM, Storm PB, Lang SS, Butler WE, Carter BS, Chapman P, Stapleton CJ, Patel AB, Rodesch G, Smajda S, Berenstein A, Barak T, Erson-Omay EZ, Zhao H, Moreno-De-Luca A, Proctor MR, Smith ER, Orbach DB, Alper SL, Nicoli S, Boggon TJ, Lifton RP, Gunel M, King PD, Jin SC, Kahle KT.
Nature Communications. 2023; 14(1): 7452.

143. Structure determination of SH2-phosphopeptide complexes by X-ray crystallography: the example of p120RasGAP.
Stiegler AL, Boggon TJ.
Methods in Molecular Biology. 2023; 2705: 77-89.
In: SH2 Domains. Humana, New York, NY. Editors: Carlomagno T, Köhn, M.

142. Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP and Dok1.
Vish KJ, Stiegler AL, Boggon TJ.
Journal of Biological Chemistry. 2023; 299(9): 105098.

141. De novo variants implicate chromatin modification, transcriptional regulation, and retinoic acid signaling in syndromic craniosynostosis.
Timberlake AT, McGee S, Allington G, Kiziltug E, Wolfe EM, Stiegler AL, Boggon TJ, Sanyoura M, Morrow M, Wenger TL, Fernandes EM, Caluseriu O, Persing JA, Jin SC, Lifton RP, Kahle KT, Kruszka P.
Am J Hum Genet. 2023; 110(5):846-862.

140. De novo mutations in the BMP signaling pathway in lambdoid craniosynostosis.
Timberlake AT, Kiziltug E, Jin SC, Nelson-Williams C, Loring E, Yale Center for Genome Analysis; Allocco A, Marlier A, Banka S, Stuart H, Passos-Buenos MR, Rosa R, Rogatto S, Tonne E, Stiegler AL, Boggon TJ, Alperovich M, Steinbacher D, Staffenberg DA, Flores RL, Persing JA, Kahle KT, Lifton RP.
Human Genetics. 2023; 142(1):21-32.

139. Tandem engagement of phosphotyrosines by the dual SH2 domains of p120RasGAP.
Stiegler AL, Vish KJ, Boggon TJ.
Structure. 2022; 30(12):1603-1614.

138. Rho family GTPase signaling through type II p21-activated kinases.
Chetty AK, Ha BH, Boggon TJ.
Cellular and Molecular Life Sciences. 2022; 79(12):598.

137. Molecular basis for integrin adhesion receptor binding to p21-activated kinase 4 (PAK4).
Ha BH, Yigit S, Natarajan N, Morse EM, Calderwood DA, Boggon TJ.
Communications Biology. 2022; 5(1):1257.

136. SH3 domain regulation of RhoGAP activity: crosstalk between p120RasGAP and DLC1 RhoGAP.
Chau JE, Vish KJ, Boggon TJ, Stiegler AL.
Nature Communications. 2022; 13(1):4788.

135. Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation.
Gao X, Liu Y, Li Y, Fan H, Wu R, Zhang R, Faubert B, He YY, Bissonnette MB, Xia S, Chen D, Mao H, Boggon TJ, Chen J.
Molecular Cell. 2022; 82(11):1992-2005.e9.

134. Tousled-like kinase 2 targets ASF1 histone chaperones through client mimicry.
Simon B, Lou HJ, Shi BG, Huet-Calderwood C, Boggon TJ, Turk BE, Calderwood DA.
Nature Communications. 2022; 13(1):749.

133. Integrated genomic analyses of cutaneous T cell lymphomas reveal the molecular bases for disease heterogeneity.
Park J, Daniels J, Wartewig T, Ringbloom KG, Martinez-Escala ME, Choi S, Thomas JJ, Doukas PG, Yang J, Snowden C, Law C, Lee Y, Lee K, Zhang Y, Conran C, Tegtmeyer K, Mo SH, Pease DR, Jothishankar B, Kwok PY, Abdulla FR, Pro B, Louissaint A, Boggon TJ, Sosman J, Guitart J, Rao DA, Ruland J, Choi J.
Blood. 2021; 138(14):1225-1236.

132. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Chen D, Xia S, Zhang R, Li Y, Famulare CA, Fan H, Wu R, Wang M, Zhu AC, Elf SE, Su R, Dong L, Arellano M, Blum WG, Mao H, Lonial S, Stock W, Odenike O, Le Beau M, Boggon TJ, He C, Chen J, Gao X, Levine RL, Chen J.
Molecular Cell. 2021; 2021; 81(18):3833-3847.

131. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.
Pan C, Li J, Kang JH, Hwang JS, Li J, Boese AC, Yang L, Wang X, Yang L, Boggon TJ, Chen GZ, Saba NF, Shin DM, Magliocca KR, Kang S.
Nature Communications. 2021; 12(1):4960.

130. Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.
Le Coz C, Nguyen DN, Su C, Nolan BE, Albrecht AV, Xhani S, Sun D, Demaree B, Pillarisetti P, Khanna C, Wright F, Chen PA, Yoon S, Stiegler AL, Maurer K, Garifallou JP, Rymaszewski A, Kroft SH, Olson Titus, Seif AE, Wertheim G, Grant SFA, Vo LT, Puck JM, Sullivan KE, Routes JM, Zakharova V, Shcherbina A, Mukhina A, Rudy NL, Hurst ACE, Atkinson TP, Boggon TJ, Hakonarson H, Abate AR, Hajjar J, Nicholas SK, Lupski JR, Verbsky J, Chinn IK, Gonzalez MV, Wells AD, Marson A, Poon GMK, Romberg N.
Journal of Experimental Medicine. 2021; 218(7):e20201750.

129. SH2 Domain Binding: Diverse FLVRs of Partnership.
Jaber Chehayeb R, Boggon TJ.
Frontiers in Endocrinology. 2020; 11:575220

128. The pseudoGTPase group of pseudoenzymes.
Stiegler AL, Boggon TJ.
FEBS Journal. 2020; 287:4232-4245

127. Recognition of physiological phosphorylation sites by p21-activated kinase 4.
Chetty AK, Sexton JA, Ha BH, Turk BE, Boggon TJ.
Journal of Structural Biology. 2020; 211(3):107553
            
126. The GTPase-activating protein p120RasGAP has an evolutionarily conserved “FLVR-unique” SH2 domain.
Jaber Chehayeb R, Wang J, Stiegler AL, Boggon TJ.
Journal of Biological Chemistry. 2020; 295(31):10511-10521

125. Crystallographic Studies of the Cerebral Cavernous Malformations Proteins.
Fisher OS, Li X, Liu W, Zhang R, Boggon TJ.
Methods in Molecular Biology. 2020;2152:291-302.

124. Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide.
Jaber Chehayeb R, Stiegler AL, Boggon TJ.
PLOS ONE. 2019;14(12):e0226113

123. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD.
Proceedings of the National Academy of Sciences, U.S.A. 2019;116(45):22730-22736

122. γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.
Gao X, Zhao L, Liu S, Li Y, Xia S, Chen D, Wang M, Wu S, Dai Q, Vu H, Zacharias L, DeBerardinis R, Lim E, Metallo C, Boggon TJ, Lonial S, Lin R, Mao H, Pan Y, Shan C, Chen J.
Molecular Cell. 2019;76(6):857-871.e9

121. Mutations in TFAP2B and previously unimplicated genes of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis.
Timberlake AT, Jin SC, Nelson-Williams C, Wu R, Furey CG, Islam B, Haider S, Loring E, Galm A; Yale Center for Genome Analysis, Steinbacher DM, Larysz D, Staffenberg DA, Flores RL, Rodriguez ED, Boggon TJ, Persing JA, Lifton RP.
Proceedings of the National Academy of Sciences, U.S.A. 2019;116(30):15116-15121

120. Clamping together hemidesmosomes and latching them in place.
Boggon TJ.
Structure. 2019;27(6):881-883

119. ARGuing for a new kinase class.
Boggon TJ.
Nature Chemical Biology. 2019;15(5):431-432

118. Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output.
Miller CJ, Lou HJ, Simpson C, van de Kooij B, Ha BH, Fisher OS, Pirman NL, Boggon TJ, Rinehart J, Yaffer MB, Linding R, Turk BE.
PLOS Biology. 2019;17(3):e2006540

117. Mutant and wild-type isocitrate dehydrogenase 1 share enhancing mechanisms involving distinct tyrosine kinase cascades in cancer.
Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J.
Cancer Discovery. 2019;9(6):756-777

116. Mutations in ILK, encoding integrin linked kinase, are associated with arrhythmogenic cardiomyopathy.
Brodehl A, Rezazadeh S, Williams T, Munsie N, Liedtke D, Oh T, Ferrier R, Shen Y, Jones SJM, Stiegler AL, Boggon TJ, Duff HJ, Friedman JM, Gibson WT, FORGE Canada Consortium, Childs SJ, Gerull B.
Translational Research. 2019;208:15-29

115. PseudoGTPase domains in p190RhoGAP proteins: a mini-review.
Stiegler AL, Boggon TJ.
Biochemical Society Transactions. 2018; 46(6):1713-1720

114. The N-terminal GTPase domain of p190RhoGAP proteins is a pseudoGTPase.
Stiegler AL, Boggon TJ.
Structure. 2018; 26(11):1451-1461.

113. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S.
Cancer Cell. 2018; 34(2):315-330.e7

112. CDC42 binds PAK4 via an extended GTPase-effector interface.
Ha BH, Boggon TJ.
Proceedings of the National Academy of Sciences, U.S.A. 2018; 115(3):531-536.

111. PAK4 crystal structures suggest unusual kinase conformational movements.
Zhang EY, Ha BH, Boggon TJ.
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2018; 1866(2):356-3657

110. The crystal structure of pseudokinase PEAK1 (Sugen Kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.
Ha BH, Boggon TJ.
Journal of Biological Chemistry. 2018; 293(5):1642-1650.

109. The repeat region of cortactin is intrinsically disordered in solution.
Li X, Tao Y, Murphy JW, Scherer AN, Lam TT, Marshall AG, Koleske AJ, Boggon TJ.
Scientific Reports. 2017; 7:16696

108. p190RhoGAP proteins contain pseudoGTPase domains.
Stiegler AL, Boggon TJ.
Nature Communications. 2017; 8(506)

107. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).
Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, Kim J, Martinez-Escala E, Amankulor N, Pro B, Guitart J, Mendillo ML, Savas JN, Boggon TJ, Choi J.
Blood. 2017; 130(12):1430-1440

106. Book review: Skills for a scientific life, by John R. Helliwell.
Boggon TJ.
Crystallography Reviews. 2017; 23(3) 227-229.

105. Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to anti-malarial agent dihydroartemisinin.
Elf S, Lin R, Xia S, Pan Y, Shan C, Lonial S, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Fan J, Lee BH, Boggon TJ, Wu S, Chen J.
Oncogene. 2017; 36(2):254-262.

104. Tetrameric acetyl-CoA acetyltransferase 1 is important for tumor growth.
Fan J, Lin R, Xia S, Chen D, Elf SE, Liu S, Pan Y, Xu H, Shan C, Zhou L, Lei Q, Li Y, Mao H, Lee BH, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Kang S, Doetsch PW, Lonial S, Boggon TJ, Curran WJ, Chen J.
Molecular Cell. 2016; 64(5):859-874.

103. Mutational landscape of uterine and ovarian carcinosarcomas reveals new recurrently-mutated histone core genes as drivers of epithelial-mesenchymal-transition.
Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick M, Edraki B, Mane S, Bilguvar K, Choi M, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.
Proceedings of the National Academy of Sciences, U.S.A. 2016; 113(43):12238-43.

102. Structural basis for noncanonical substrate recognition of cofilin/ADF proteins by LIM kinases.
Hamill S, Lou HJ, Turk BE, Boggon TJ.
Molecular Cell. 2016; 62(3):397-408.

101. Recurrent recessive mutation in DGUOK causes idiopathic non-cirrhotic portal hypertension.
Vilarinho S, Sari S, Yilmaz G, Stiegler AL, Boggon TJ, Jain D, Akyol G, Dalgic B, Günel M, Lifton RP.
Hepatology. 2016;

100. Data publication with the structural biology data grid supports live analysis.
Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Christopher Fromme J, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P.
Nature Communications. 2016; 7:10882

99. PAK6 targets to cell-cell adhesions via its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.
Morse EM, Sun X, Olberding JR, Ha BH, Boggon TJ, Calderwood DA.
Journal of Cell Science. 2016; 129(2):380-93.

98. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J.
Nature Cell Biology. 2015; 17(11):1484-96.

97. Structural analysis of the KRIT1 ankyrin repeat and FERM domains reveals a conformationally stable ARD–FERM interface.
Zhang R, Li X, Boggon TJ.
Journal of Structural Biology. 2015; 192(3):449-56.

96. The cerebral cavernous malformations proteins.
Li X, Fisher OS, Boggon TJ.
Oncotarget. 2015; 6(32):32279-80.

95. Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex.
Fisher OS*, Deng H*, Liu D*, Zhang Y, Wei R, Deng Y, Zhang F, Louvi A, Turk BE, Boggon TJ, Su B.
Nature Communications. 2015; 6:7937. doi:10.1038/ncomms8937

94. Genomic landscape of cutaneous T cell lymphoma.
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP.
Nature Genetics. 2015; 2015; 47(9):1011-1019.

93. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J.
Molecular Cell. 2015; 59(3):345.58.

92. AIP1 expression in tumor niche suppresses tumor progression and metastasis.
Ji W, Li Y, He Y, Yin M, Zhou HJ, Boggon TJ, Zhang H, Min W.
Cancer Research. 2015; 75(17):3492-504

91. Signaling, regulation and specificity of the type II p21-activated kinases.
Ha BH, Morse EM, Turk BE, Boggon TJ
Journal of Biological Chemistry. 2015; 290(21):12975-12983.

90. CCM2-CCM3 interaction stabilizes their protein expression and permits endothelial network formation.
Draheim KM*, Li X*, Zhang R, Fisher OS, Villari G, Boggon TJ, Calderwood DA.
Journal of Cell Biology. 2015; 208 (7):987-1001.

89. Crystal structure of ABL2/ARG kinase in complex with Dasatinib.
Ha BH, Simpson A, Koleske AJ, Boggon TJ.
Acta Crystallogr F Structural Biology and Crystallization Communications. 2015; 71. doi:10.1107/S2053230X15004793

88. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.
Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S.
Cancer Cell. 2015; 27(2):257-70.

87. Structural basis for the disruption of the Cerebral Cavernous Malformations 2 (CCM2) interaction with Krev Interaction Trapped 1 (KRIT1) by disease-associated mutations.
Fisher OS, Liu W, Zhang R, Stiegler AL, Ghedia S, Weber JL, Boggon TJ.
Journal of Biological Chemistry. 2015; 290(5):2842-53.

86. The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer.
Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J.
Molecular Cell. 2015; 57(1):191-201.

85. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation.
Romberg N, Moussawi KA, Nelson-Williams C, Stiegler AL, Loring E, Choi M, Overton J, Meffre E, Khokha MK, Huttner AJ, West B, Podoltsev NA, Boggon TJ, Kazmierczak BI, Lifton RP.
Nature Genetics. 2014; 46(10):1135-9.

84. Global analysis of human non-receptor tyrosine kinase specificity using high-density peptide microarrays.
Deng Y, Alicea-Velazquez NL, Bannwarth L, Lehtonen SI, Boggon TJ, Cheng HC, Hytonen V, Turk BE.
Journal of Proteome Research. 2014; 13(10):4339-46.

83. Tyr-301 phosphorylation inhibits pyruvate dehydrogenase through and additional and independent mechanism by blocking substrate binding, and promotes the Warburg effect.
Fan J, Kang HB, Shan C, Elf S, Lin R, Xie J, Gu TL, Aguiar M, Lonning S, Chung TW, Arellano M, Khoury HJ, Shin DM, Khuri FR, Boggon TJ, Kang S, Chen J.
Journal of Biological Chemistry. 2014; 289(38):26533-41.

82. Differences in binding to the ILK complex determines kindlin isoform adhesion localization and integrin activation.
Huet-Calderwood C, Brahme NN, Kumar N, Stiegler AL, Raghavan S, Boggon TJ, Calderwood DA.
Journal of Cell Science. 2014; 127(Pt 19):4308-21.

81. Structural determinants for binding of Sorting Nexin 17 (SNX17) to the cytoplasmic adaptor protein Krev Interaction Trapped 1 (KRIT1)
Stiegler AL, Zhang R, Liu W, Boggon TJ.
Journal of Biological Chemistry. 2014; 289(36):25362-73.

80. Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth.
Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, Jin L, Lin R, Zhang L, Seo JH, Xie J, Tucker M, Gu TL, Hu Z, Sudderth J, Jiang L, DeBeradinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J.
Molecular Cell. 2014; 55:1-14.

79. Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth.
Shan C, Kang HB, Elf S, Xie J, Gu TL, Aguiar M, Lonning S, Hitosugi T, Chung TW, Arellano M, Khoury HJ, Shin DM, Khuri FR, Boggon TJ, Fan J.
Journal of Biological Chemistry. 2014; 289(31):21413-21422.

78. Two Amino Acid Residues Confer Different Binding Affinities of Abelson Family Kinase Src Homology 2 Domains for Phosphorylated Cortactin.
Gifford SM*, Liu W*, Mader CC, Halo TL, Machida K, Boggon TJ, Koleske AJ.
Journal of Biological Chemistry. 2014; 289(28):19704-19713.

77. Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex.
Fan J, Shan C, Kang HB, Elf S, Xie J, Tucker M, Gu TL, Aguiar M, Lonning S, Chen H, Mohammadi M, Britton LM, Garcia BA, Alečković M, Kang Y, Kaluz S, Devi N, Van Meir EG, Hitosugi T, Seo JH, Lonial S, Gaddh M, Arellano M, Khoury HJ, Khuri FR, Boggon TJ, Kang S, Chen J.
Molecular Cell. 2014; 53(4):1-15.

76. Cerebral cavernous malformation proteins at a glance.
Draheim KM, Fisher OS, Boggon TJ, Calderwood DA.
Journal of Cell Science. 2014; 127(4):701-7.

75. Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity.
Chen C*, Ha BH*, Thevenin AF, Lou HJ, Zhang R, Yip KY, Peterson JR, Gerstein M, Kim PM, Filippakopoulos P, Knapp S, Boggon TJ, Turk BE.
Molecular Cell. 2014; 53(1):140-147.

74. Identification of PLX4032-Resistance Mechanisms and Implications for Novel RAF Inhibitors.
Choi J, Landrette S, Wang T, Evans P, Bacchiocchi A, Bjornson R, Cheng E, Stiegler AL, Gathiaka S, Acevedo O, Boggon TJ, Krauthammer M, Halaban R, Xu T.
Pigment Cell Melanoma Research. 2014; 27(2):253-62.

73. Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.
Fisher OS, Boggon TJ.
Cellular and Molecular Life Sciences. 2014; 71(10):1881-92.

72. Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia.
Shibata S, Rinehart J, Zhang J, Moeckel G, Castaneda-Bueno M, Stiegler AL, Boggon TJ, Gamba G, Lifton RP.
Cell Metabolism. 2013; 18(5): 660-671.

71. A network of interactions enables CCM3 and STK24 to coordinate UNC13D-driven vesicle exocytosis in neutrophils.
Zhang Y, Tang W, Zhang H, Niu X, Xu Y, Zhang J, Gao K, Pan W, Boggon TJ, Toomre D, Min W, Wu D.
Developmental Cell. 2013; 27(2): 215-226.

70. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.
Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J.
Proceedings of the National Academy of Sciences, U.S.A. 2013; 110(44): 17832-7.

69. Substrate and inhibitor specificity of the type II p21-activated kinase, PAK6.
Gao J, Ha BH, Lou HJ, Morse EM, Zhang R, Calderwood DA, Turk BE, Boggon TJ.
PLOS ONE. 2013; 8(10): e77818.

68. Cocrystal structure of ICAP1 PTB domain in complex with a KRIT1 peptide.
Liu W, Boggon TJ.
Acta Crystallogr F Structural Biology and Crystallization Communications. 2013; 69: 494-498.

67. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Hitosugi T, Zhou L, Fan J, Elf S, Zhang L, Xie J, Wang Y, Gu TL, Aleckovic M, LeRoy G, Kang Y, Kang HB, Seo JH, Shan C, Jin P, Gong W, Lonial S, Arellano M, Khoury J, Chen ZG, Shin DM, Khuri FR, Boggon TJ, Kang S, He C, Chen J.
Nature Communications. 2013 4:1790.

66. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF.
Pigment Cell and Melanoma Research. 2013; 26(4):527-41.

65. p90RSK2 mediates anti-anoikis signals by both transcription-dependent and -independent mechanisms.
Jin L, Li D, Lee JS, Elf S, Alesi GN, Fan J, Kang HB, Wang D, Fu H, Taunton J, Boggon TJ, Tucker M, Gu TL, Chen ZG, Shin DM, Khuri FR, Kang S.
Mol. Cell. Biol. 2013; 33(13):2574-85.

64. SHP family protein tyrosine phosphatases adopt canonical active-site conformations in the apo and phosphate-bound states.
Alicea-Velazquez NL, Boggon TJ.
Protein Pept Lett. 2013; 20(9):1039-48.

63. Purification and SAXS analysis of the Integrin Linked Kinase, PINCH, parvin (IPP) heterotrimeric complex.
Stiegler AL, Grant TD, Luft JR, Calderwood DA, Snell EH, Boggon TJ.
PLOS ONE. 2013; 8(1):e55591.

62. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.
Proceedings of the National Academy of Sciences, U.S.A. 2013; 110(8):2916-2921.

61. Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration.
Bilguvar K, Tyagi NK, Ozkara C, Tuysuz B, Bakircioglu M, Choi M, Delil S, Caglayan AO, Baranoski JF, Erturk O, Yalcinkaya C, Karacorlu M, Dincer A, Johnson MH, Mane S, Chandra SS, Louvi A, Boggon TJ, Lifton RP, Horwich AL, Gunel M.
Proceedings of the National Academy of Sciences, U.S.A. 2013; 110(9):3489-3494.

60. Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin activation.
Liu W*, Draheim*, Zhang R, Calderwood DA, Boggon TJ.
Molecular Cell. 2013; 49(4):719-29.
Research highlights.

59. Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition.
Alicea-Velazquez NL, Jakoncic J, Boggon TJ.
Journal of Structural Biology. 2013; 181(3):243-51

58. RAC1-P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ.
Proceedings of the National Academy of Sciences, U.S.A. 2013; 110(3):912-917. 
News and Views in PCMR

57. Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its C-terminus.
Fisher OS, Zhang R, Li X, Murphy JW, Demeler B, Boggon TJ.
FEBS Letters. 2013; 587(3):272-7.

56. Phosphoglycerate Mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, Gu TL, Jin P, Aleckovic M, LeRoy G, Kang Y, Sudderth JA, DeBerardinis RJ, Luan CH, Chen GZ, Muller S, Shin DM, Owonikoko TK, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Ye K, Boggon TJ, Kang S, He C, Chen J.
Cancer Cell. 2012; 22(5):585-600

55. Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.
Ha BH, Davis MJ, Chen C, Lou HJ, Gao J, Zhang R, Krauthammer M, Halaban R, Schlessinger J, Turk BE, Boggon TJ.
Proceedings of the National Academy of Sciences, U.S.A. 2012; 109(40):16107-16112

54. Understanding the molecular and functional mechanisms that underlie pharamcogenomics-based therapy.
Ha BH and Boggon TJ.
J Pharmacogenomics Pharmacoproteomics. 2012; 3:e122

53. Structural basis for paxillin binding and focal adhesion targeting of beta-parvin.
Stiegler AL, Draheim KM, Li X, Chayen NE, Calderwood DA, Boggon TJ.
Journal of Biological Chemistry. 2012; 287(39):32566-32577

52. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.
Nature Genetics. 2012; 44(9):1006-1014

51. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.
Nature Genetics. 2012; 44(8):852-860

50. Structural basis for the small G-protein-effector interaction of Ras-related protein 1 (Rap1) and the adaptor protein Krev interaction trapped 1 (KRIT1).
Li X, Zhang R, Draheim KM, Liu W, Calderwood DA, Boggon TJ
Journal of Biological Chemistry. 2012; 287(26):22317-22327

49. Calcium-induced conformational changes in the C-terminal tail of polycystin-2 are necessary for channel gating.
Celic AS*, Petri ET*, Benbow J, Hodsdon ME, Ehrlich BE, Boggon TJ.
Journal of Biological Chemistry. 2012; 287(21):17232-17240

48. Lysozyme contamination facilitates crystallization of a hetero-trimeric Cortactin:Arg:Lysozyme complex.
Liu W, MacGrath SM, Koleske AJ, Boggon TJ.
Acta Crystallogr F Structural Biology and Crystallization Communications. 2012; 68(2): 154-158.

47. Tyrosine phosphorylation of LDH-A is important for NADH/NAD+ redox homeostasis in cancer cells.
Fan J, Hitosugi T, Chung, TW, Xie J, Ge Q, Gu TL, Polakiewicz RD, Chen GZ, Boggon TJ, Lonial S, Khuri FR, Kang S, and Chen J.
Molecular and Cellular Biology. 2011; 31(24):4938-4950.

46. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.
Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen Z, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J.
Molecular Cell. 2011; 44:864-877.

45. Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting-homology domain of cerebral cavernous malformation 3 (CCM3).
Li X, Ji W, Zhang R, Folta-Stogniew E, Min W, Boggon TJ.
Journal of Biological Chemistry. 2011; 286(29):26138-26147.

44. The use of structural biology in Janus kinase targeted drug discovery.
Alicea-Velazquez NL, Boggon TJ.
Current Drug Targets. 2011; 12(4):546-55

43. EGFR-mutated lung cancer: a paradigm of molecular oncology.
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B.
Oncotarget. 2010; 1:497-514

42. Crystal structure of CCM3, a cerebral cavernous malformation protein critical for vascular integrity.
Li X*, Zhang R*, Zhang H, He Y, Ji W, Min W, Boggon TJ.
Journal of Biological Chemistry. 2010; 285(31):24099-24107

41. Structure of the EF-hand domain of polycystin-2 suggests a mechanism for Ca2+-dependent regulation of polycystin-2 channel activity.
Petri ET, Celic AS, Kennedy SD, Ehrlich BE, Boggon TJ, Hodsdon ME.
Proceedings of the National Academy of Sciences, U.S.A. 2010; 107(20):9176-81

40. Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development.
He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H, Min W
Science Signaling. 3(116), ra26

39. An asymmetric inter-receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.
Bae JH, Boggon TJ, Tome F, Mandiyan V, Lax I, Schlessinger, J
Proceedings of the National Academy of Sciences, U.S.A.  2010; 107(7):2866-2871

38. Structural basis of competition between PINCH2 and PINCH1 for binding to the ankyrin repeat domain of integrin-linked kinase.
Chiswell BP, Stiegler AL, Razinia Z, Boggon TJ, Calderwood DA
Journal of Structural Biology. 2010; 70(1):157-163

37. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.
Science Signaling. 2009; 2(97):ra73

36. JAK3: a two-faced player in hematological disorders.
Cornejo MG, Boggon TJ, Mercher T.
International Journal of Biochemistry and Cell Biology. 2009; 41(12):2376-9.

35. Analysis of the cytoplasmic interaction between polycystin-1 and polycystin-2.
Casuscelli J*, Schmidt S*, DeGray B, Petri ET, Celic A, Folta-Stogniew E, Ehrlich BE, Boggon TJ.
American Journal of Physiology, Renal Physiology. 2009; 297 (5): F1310-1315

34. Genetic abnormalities of the EGFR pathway in African-American patients with Non-Small Cell Lung Cancer.
Leidner RS, Fu P, Clifford B, Hamdan A, Cheng J, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, Cappuzzo F, Hirsch FR, Varella-Garcia M, Halmos B.
Journal of Clinical Oncology. 2009; 27(33):5620-6.

33. FGFR3 associates with and tyrosine-phosphorylates p90RSK2, leading to RSK2 activation that mediates hematopoietic transformation.
Kang S, Elf S, Dong S, Hitosugi T, Lythgoe K, Guo A, Ruan H, Lonial S, Khoury HJ, Williams IR, Lee, BH, Roesel JL, Karsenty G, Hanauer A, Taunton J, Boggon TJ, Gu TL, Chen J.
Molecular and Cellular Biology. 2009; 29(8):2105-17.

32. The structural basis of integrin-linked kinase-PINCH interactions.
Chiswell BP, Zhang R, Murphy JW, Boggon TJ, Calderwood DA.
Proceedings of the National Academy of Sciences, U.S.A. 2008; 105(52):20677-20682

31. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC.
Oncogene. 2008; 28(4):518-33

30. Domain mapping of the polycystin-2 C-terminal tail using de novo molecular modeling and biophysical analysis.
Celic A*, Petri ET*, Demeler B, Ehrlich BE, Boggon TJ.
Journal of Biological Chemistry. 2008; 283(42):28305-12

29. The Structure and Clinical Relevance of the EGF Receptor in Human Cancer.
Kumar A*, Petri ET*, Halmos B, Boggon TJ.
Journal of Clinical Oncology. 2008; 29(10):1742-51.

28. Structural and numerical variation of FLT3/ITD in pediatric AML.
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP.
Blood. 2008; 111(10):4930-3.

27. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.
Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG.
Cancer Cell. 2007; 12(6):501-13.

26. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.
Cancer Research. 2007; 67(21):10417-27.

25. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
PLoS Medicine. 2007; 4(10):1669-79.

24. Automated Protein Crystallization Trials using the Thermo Scientific Matrix Hydra II eDrop.
Murthy TV, Wang Y, Reynolds C, Boggon TJ.
Journal of the Association for Laboratory Automation. 2007; 12(4):213-218.

23. Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity.
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ.
Cancer Cell. 2007; 11(3):217-27.

22. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK, Mercher T, Gu TL, O'hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ.
Cancer Cell. 2006; 10(1):65-75.

21. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Frohling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG
Blood. 2006; 108(8):2770-9.

20. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
Boggon TJ, Li Y, Manley PW, Eck MJ
Blood. 2005;106(3):996-1002.

19. Activating mutation in the tyrosine kinase Jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG
Cancer Cell. 2005;7(4):387-397.

18. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B
New England Journal of Medicine. 2005;352(8):786-92.

17. Structure and regulation of Src family kinases.
Boggon TJ, Eck MJ
Oncogene. 2004;23(48):7918-27.

16. Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR
Blood. 2004;104(6):1855-8.

15. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M
Science. 2004;304(5676):1497-500.

14. Apocrustacyanin C1 crystals grown in space and on earth using vapour-diffusion geometry: protein structure refinements and electron-density map comparisons.
Habash J, Boggon TJ, Raftery J, Chayen NE, Zagalsky PF, Helliwell JR
Acta Crystallogr D Biol Crystallogr. 2003;59(7):1117-23.

13. C-Cadherin ectodomain structure and implications for cell adhesion mechanisms.
Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L
Science. 2002;296(5571):1308-13.

12. G-Protein Signaling Through Tubby Proteins.
Santagata S, Boggon TJ, Baird CL, Gomez CA, Zhao J, Shan WS, Myszka DG, Shapiro L
Science. 2001;292(5524):2041-50.

11. Screening for phasing atoms in protein crystallography.
Boggon TJ, Shapiro L
Structure. 2000;8:R143-R149.

10. Synchrotron X-ray reciprocal-space mapping, topography and diffraction resolution studies of macromolecular crystal quality.
Boggon TJ, Helliwell JR, Judge RA, Olczak A, Siddons DP, Snell EH, Stojanoff V
Acta Crystallogr D Biol Crystallogr. 2000;56(7):868-80.

9. Implication of tubby proteins as transcription factors by structure-based functional analysis.
Boggon TJ, Shan WS, Santagata S, Myers SC, Shapiro L
Science. 1999;286(5447):2119-25.

8. Purification, crystallization and initial X-ray analysis of the C1 subunit of the astaxanthin protein, V600, of the chondrophore Velella velella.
Chayen NE, Boggon TJ, Raftery J, Helliwell JR, Zagalsky PF
Acta Crystallogr D Biol Crystallogr. 1999;55(1):266-8.

7. Bound-solvent structures for microgravity-, ground control-, gel- and microbatch-grown hen egg-white lysozyme crystals at 1.8 Å resolution.
Dong J, Boggon TJ, Chayen NE, Raftery J, Bi RC, Helliwell JR
Acta Crystallogr D Biol Crystallogr. 1999;55(4):745-52.

6. Protein crystal movements and fluid flows during microgravity growth.
Boggon TJ, Chayen NE, Snell EH, Dong J, Lautenschlager P, Potthast L, Siddons DP, Stojanoff V, Gordon E, Thompson AW, Zagalsky PF, Bi RC, Helliwell JR
Phil. Trans. R. Soc. Lond. A. 1998;356(1739):1045-61.

5. Partial improvement of crystal quality for microgravity grown apocrustacyanin C1.
Snell EH, Cassetta A, Helliwell JR, Boggon TJ, Weckert E, Holzer K, Schroer K, Gordon EJ, Zagalsky PF
Acta Crystallogr D Biol Crystallogr. 1997;53:231-9.

4. CCD video observation of microgravity crystallization of lysozyme and correlation with accelerometer data.
Snell EH, Boggon TJ, Helliwell JR, Moskowitz ME, Nadarajah A
Acta Crystallogr D Biol Crystallogr. 1997;53:747-55.

3. Lysozyme crystal growth kinetics monitored using a Mach-Zehnder interferometer.
Snell EH, Helliwell JR, Boggon TJ, Lautenschlager P, Potthast L
Acta Crystallogr D Biol Crystallogr. 1996;52:529-33.

2. Trends and challenges in experimental macromolecular crystallography.
Chayen NE, Boggon TJ, Cassetta A, Deacon A, Gleichmann T, Habash J, Harrop SJ, Helliwell JR, Nieh YP, Peterson MR, Raftery J, Snell EH, Hadener A, Niemann AC, Siddons DP, Stojanoff V, Thompson AW, Ursby T, Wulff M
Q Rev Biophys. 1996;29(3):227-78.

1. The crystal structure analysis of d(CGCGAASSCGCG)2, a synthetic DNA dodecamer duplex containing four 4'-thio-2'-deoxythymidine nucleotides.
Boggon TJ, Hancox EL, McAuley-Hecht KE, Connolly BA, Hunter WN, Brown T, Walker RT, Leonard GA
Nucleic Acids Res. 1996;24(5):951-61.